This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. It will also create reusable infrastructure to allow creation or affiliation with many additional RWD/RWE efforts both prospective and retrospective in nature.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Best overall response (BOR) - 1st line of therapy
Timeframe: 1st line of therapy, on average less than 1 year
Best overall response (BOR) - 2nd line of therapy
Timeframe: 2nd line of therapy, on average less than 1 year
Best overall response (BOR) - 3rd line of therapy
Timeframe: 3rd line of therapy, on average less than 1 year
Best overall response (BOR) - 4th line of therapy
Timeframe: 4th line of therapy, on average less than 1 year
Best overall response (BOR) - 5th line of therapy
Timeframe: 5th line of therapy, on average less than 1 year
Progression-free survival (PFS) - 1st line of therapy
Timeframe: 1st line of therapy, on average less than 1 year
Progression-free survival (PFS) - 2nd line of therapy
Timeframe: 2nd line of therapy, on average less than 1 year
Progression-free survival (PFS) - 3rd line of therapy
Timeframe: 3rd line of therapy, on average less than 1 year
Progression-free survival (PFS) - 4th line of therapy
Timeframe: 4th line of therapy, on average less than 1 year
Progression-free survival (PFS) - 5th line of therapy
Timeframe: 5th line of therapy, on average less than 1 year